UCrest Bhd (0005) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of UCrest Bhd stock MYR 0.03, price MYR 0.06, that is 50.0% below the price, quality 39 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 0.0500 MYR – 0.3600 MYR · the 0.0600 MYR price screens above the 0.0300 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow UCrest Bhd in your weekly email
Every Wednesday you see whether UCrest Bhd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
UCrest Berhad, an investment holding company, engages in the design, development, and marketing of information technology related products and services in Malaysia and Singapore.
Show moreShow less
The company offers iMedic cloud hospital that is used by doctors and patients for the diagnosis, management, and treatment of chronic diseases, such as cardiovascular diseases (CVD), cancer, diabetes, hypertension, sleep apnea, stroke rehabilitation, and other diseases in the United States, China, Singapore, Malaysia, Taiwan, Indonesia, Vietnam, and the Middle East.
It also provides mobile healthcare services. The company was formerly known as Palette Multimedia Berhad and changed its name to UCrest Berhad in November 2017. UCrest Berhad was incorporated in 1997 and is based in Petaling Jaya, Malaysia.
Stock analysis
UCrest Bhd (0005) currently trades at 0.0600 MYR, while our model-based Fair Value estimate is 0.0300 MYR, 50% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 0.0400 MYR per share, and 1 of the 6 models we run sit above the 0.0600 MYR price.
Bear case: the Multiples group reads lowest at 0.0100 MYR, and 5 of the 6 models stay below the price. Data coverage for this calculation is low.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
UCrest Bhd reported revenue of 14.0M MYR in FY2025 versus 12.3M MYR in FY2021, a compound +3.1%/yr. Reported net income was 269K MYR in FY2025.
Key figures
Market cap 44.6M MYR (≈ $11.0M) Micro · P/S ratio 2.93 · Net margin 1.9% · Return on equity 0.6% · Return on assets (EBIT) −17.7% · Operating margin −12.0% · Revenue (TTM) 14.0M MYR · Revenue growth (YoY) −1.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −50%, 0005 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (0.0100 MYR to 0.1500 MYR). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear0.0300 MYRFair Value 0.0300 MYRBull0.0300 MYR
Price 0.0600 MYR · Downside -50.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.8/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−23.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.3%
Start year 2020 (pandemic). Over 10 years: +14.4% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−54.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−54.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−54.5% vs −25.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.46% → −23%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 118 stocks
Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−50.0% · Below median
Profitability
Return on equity (12 months)0.6% · Below median
Return on assets0.6% · Below median
Net margin (12 months)1.9% · Below median
Operating margin (12 months)−12.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−1.7% · Bottom 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B1.06× · Cheapest 25%
P/S (12 months)3.20× · Pricier than median
EV/EBITDA35.2× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 41
PAST (return on equity)2· sector 10
HEALTH (low debt)0· sector 98
DIVIDEND (yield)0· sector 36
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "UCrest Bhd Fair Value". https://www.fairvalue-calculator.com/stock/0005
Frequently asked questions
Is UCrest Bhd (0005) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 0.0300 MYR versus a price of 0.0600 MYR, about 50% lower (overvalued).
What is the fair value of 0005?
Our model-based fair value for UCrest Bhd is 0.0300 MYR (as of Nov 4, 2026), built from audited fundamentals. The current price: 0.0600 MYR.
What is the quality score of 0005?
UCrest Bhd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for UCrest Bhd (0005)?
Our model-based price target is the fair value of 0.0300 MYR (as of Nov 4, 2026) from 6 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the UCrest Bhd stock forecast for 2026?
Our models put fair value at 0.0300 MYR, about 50% lower versus a price of 0.0600 MYR (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of UCrest Bhd (0005)?
UCrest Bhd reported trailing-twelve-month revenue of about 14.0M MYR (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of UCrest Bhd (0005)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For UCrest Bhd it is 0.0300 MYR per share (as of Nov 4, 2026), against a price of 0.0600 MYR. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is UCrest Bhd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 0005 trades above its calculated fair value: price 0.0600 MYR, fair value 0.0300 MYR, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0005?
No. The price is what the market pays today (0.0600 MYR); the fair value is what the company's own numbers justify (0.0300 MYR). For UCrest Bhd the two are 0.0300 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is UCrest Bhd worth?
The market values UCrest Bhd at about 44.6M MYR (market capitalisation, as of Nov 4, 2026). Per share that is 0.0600 MYR; our models calculate a fair value of 0.0300 MYR per share.
How solid is the balance sheet of UCrest Bhd (0005)?
Balance-sheet figures for UCrest Bhd (as of Nov 4, 2026): return on equity 0.6%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 0005 from its 52-week high?
UCrest Bhd trades at 0.0600 MYR, about 29% below its 52-week high of 0.0850 MYR and 20% above the low of 0.0500 MYR (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0300 MYR is for.
Which stocks are comparable to UCrest Bhd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is UCrest Bhd stock attractive at the current price?
The data as of Nov 4, 2026: price 0.0600 MYR, calculated fair value 0.0300 MYR (−50%), Quality Score 39/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0005 calculated?
We run UCrest Bhd through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0300 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. UCrest Bhd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of UCrest Bhd (0005)?
The closing price on Nov 5, 2026 was 0.0600 MYR. Our model-based fair value is 0.0300 MYR, about 50% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with UCrest Bhd right now?
The price sits above even our optimistic bull case (0.0300 MYR). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of UCrest Bhd
How large is the market capitalisation of UCrest Bhd (0005)?
The market capitalisation of UCrest Bhd is 44.6M MYR (≈ $11.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of UCrest Bhd (0005)?
The price-to-sales ratio of UCrest Bhd is 2.93 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of UCrest Bhd (0005)?
The net margin of UCrest Bhd is 1.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of UCrest Bhd (0005)?
The return on equity (ROE) of UCrest Bhd is 0.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of UCrest Bhd (0005)?
On an EBIT basis the return on assets of UCrest Bhd is −17.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of UCrest Bhd (0005)?
The operating margin of UCrest Bhd is −12.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at UCrest Bhd (0005)?
Revenue at UCrest Bhd is growing −1.7% versus a year earlier (3y avg +1.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at UCrest Bhd (0005)?
Earnings per share at UCrest Bhd are growing −59.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does UCrest Bhd (0005) generate?
The free cash flow of UCrest Bhd is −4.9M MYR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch UCrest Bhd in the live analysis
One click puts UCrest Bhd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026
